Shanghai Financial Statements From 2010 to 2025
| SHJBF Stock | USD 2.99 1.24 29.31% |
Check Shanghai Junshi financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shanghai Junshi's main balance sheet or income statement drivers, such as , as well as many indicators such as . Shanghai financial statements analysis is a perfect complement when working with Shanghai Junshi Valuation or Volatility modules.
Shanghai |
Shanghai Junshi Biosciences Company Return On Equity Analysis
Shanghai Junshi's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Shanghai Junshi Return On Equity | -0.28 |
Most of Shanghai Junshi's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Junshi Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Shanghai Junshi Biosciences has a Return On Equity of -0.284. This is 98.82% lower than that of the Healthcare sector and 99.22% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 8.39% lower than that of the firm.
Shanghai Junshi Bios Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Junshi's current stock value. Our valuation model uses many indicators to compare Shanghai Junshi value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Junshi competition to find correlations between indicators driving Shanghai Junshi's intrinsic value. More Info.Shanghai Junshi Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Shanghai Junshi's earnings, one of the primary drivers of an investment's value.About Shanghai Junshi Financial Statements
Shanghai Junshi stakeholders use historical fundamental indicators, such as Shanghai Junshi's revenue or net income, to determine how well the company is positioned to perform in the future. Although Shanghai Junshi investors may analyze each financial statement separately, they are all interrelated. For example, changes in Shanghai Junshi's assets and liabilities are reflected in the revenues and expenses on Shanghai Junshi's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Shanghai Junshi Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, neurologic, and infectious diseases in the Peoples Republic of China. The company was founded in 2012 and is headquartered in Shanghai, Peoples Republic of China. Shanghai Junshi operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2453 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Shanghai Pink Sheet
Shanghai Junshi financial ratios help investors to determine whether Shanghai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Junshi security.